Kinetics of CO and NO Ligation with the Cys331 right-arrow  Ala Mutant of Neuronal Nitric-oxide Synthase*

Jürgen S. ScheeleDagger , Eric Bruner§, Tomasz ZemojtelDagger , Pavel Martásek, Linda J. Roman, Bettie Sue Siler Masters, Vijay S. Sharma||, and Douglas Magde§**

From the Dagger  Department of Medicine, University of Freiburg, D-79106 Freiburg, Germany, § Department of Chemistry and Biochemistry and || Department of Medicine, University of California at San Diego, La Jolla, California 92093-0358, and  Department of Biochemistry, University of Texas Health Science Center, San Antonio, Texas 78284-7760

Received for publication, August 16, 2000, and in revised form, October 13, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Nitric-oxide synthases (NOS) catalyze the conversion of L-arginine to NO, which then stimulates many physiological processes. In the active form, each NOS is a dimer; each strand has both a heme-binding oxygenase domain and a reductase domain. In neuronal NOS (nNOS), there is a conserved cysteine motif (CX4C) that participates in a ZnS4 center, which stabilizes the dimer interface and/or the flavoprotein-heme domain interface. Previously, the Cys331 right-arrow Ala mutant was produced, and it proved to be inactive in catalysis and to have structural defects that disrupt the binding of L-Arg and tetrahydrobiopterin (BH4). Because binding L-Arg and BH4 to wild type nNOS profoundly affects CO binding with little effect on NO binding, ligand binding to the mutant was characterized as follows. 1) The mutant initially has behavior different from native protein but reminiscent of isolated heme domain subchains. 2) Adding L-Arg and BH4 has little effect immediately but substantial effect after extended incubation. 3) Incubation for 12 h restores behavior similar but not quite identical to that of wild type nNOS. Such incubation was shown previously to restore most but not all catalytic activity. These kinetic studies substantiate the hypothesis that zinc content is related to a structural rather than a catalytic role in maintaining active nNOS.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Nitric-oxide synthases (NOS)1 constitute a family of heme-thiolate-liganded proteins that catalyze the conversion of L-Arg to NO and L-citrulline, requiring NADPH and molecular O2 (1). Three isoforms of mammalian NOS are known. Neuronal nitric-oxide synthase (nNOS) and endothelial nitric-oxide synthase (eNOS) are constitutively expressed and are Ca2+/calmodulin-dependent; inducible nitric-oxide synthase (iNOS) is immunostimulated and Ca2+-independent. All three are homodimers in their physiologic states; each monomer has a molar mass between about 130 and 160 kDa. In each monomer, an oxygenase domain is recognized that contains the heme (2-5) and requires tetrahydrobiopterin (BH4) (6-8). All isoforms also have a reductase domain, which is not of direct interest here.

A recent study (9) prepared nNOS (rat brain) protein with the point mutation C331A expressed in Escherichia coli. The mutant was characterized with respect to catalytic activity, the binding of BH4 and substrates, the state of the iron as deduced from EPR, and UV-visible spectral features. Because E. coli produces neither BH4 nor calmodulin, the preparation is valuable for investigating reconstitution with those factors. That report should be consulted for the several hypotheses that motivated the investigation and for an extensive list of citations. In this study, we added a brief account of the kinetics of ligand binding. The major effect of the mutation was that C331A failed to bind either BH4 or L-Arg. Arginine affinity was suppressed at least 100-fold, and the binding of BH4 was undetectable at least for some time after mixing. However, extended incubation (~12 h) with L-Arg restored essentially normal behavior, including binding of BH4 and almost full catalytic activity. Because L-Arg substrate and BH4 bind near the heme, the findings (9) suggested that "the primary dysfunction  ... is a distorted or floppy heme pocket." As to the reason for that dysfunction, the suggestion was made that Cys331 is required for binding zinc at a tetrathiolate site (10) (discovered just as the work with the mutant was being completed) and that loss of zinc perturbs the structure, especially near the heme site.

Because conformational defects (as might be introduced by mutations) on either the proximal or distal side of the heme can have dramatic effects on ligand binding, it seemed useful to us to characterize the kinetics of heme ligation for CO and NO. That would test the conclusion that the pocket is initially distorted and would provide a very sensitive test of the ability of incubation with L-Arg to restore normal functionality.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Carbon monoxide (99.8%), nitric oxide (99.9%), high purity argon, and mixtures of CO (1-100%) and NO (0.1-10%) diluted in argon were from Matheson. Nitric oxide was further purified through a column of fresh KOH. Buffers (20 mM Tris-HCl, pH 7.8, 100 µM EDTA, 100 mM NaCl) were prepared in a gas-tight syringe and deoxygenated by bubbling with argon for 40 min. When indicated, buffers contained 250 µM BH4 and/or L-Arg at concentrations of 0.1-10 mM.

The point mutation C331A in rat nNOS was generated as reported previously (9). The proteins were >90% homogeneous as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Protein solutions were degassed and then added to the buffer with the desired ligand concentration. As needed, the protein solutions were reduced using one part in 50 of 1% sodium dithionite solution. Overnight incubations of protein with L-Arg were carried out at 3 °C. Spectra were consistent with previously published data (9, 11-13).

Flash photolysis was carried out at 22 °C using procedures described previously (14, 15). Kinetics were monitored at several wavelengths showing both transient absorption and initial state bleaching. Stopped-flow measurements were carried out at 20 °C following protocols described earlier (16). Carbon monoxide dissociation rates were determined by replacing CO with NO (17). After mixing, samples contained 0.5 µM protein, 25 µM sodium dithionite, 500 µM CO, and 1000 µM NO. (For the ferrous hemes, which alone bind CO, affinity for NO is much larger than for CO.) Absorption changes were monitored at 443 nm.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

CO Ligation-- UV-visible spectra for the C331A mutant itself and its association with CO were reported previously (9). The kinetics of CO binding for both the C331A mutant and WT nNOS display two phases for concentration-dependent bimolecular combination that differ in rate by a factor of 100. A typical example of absorption changes following flash photolysis is shown in Fig. 1. Mutant and WT nNOS are similar in that fast and slow phases are not perfect single exponentials but require two or more rate constants distributed over a range of a factor of 3 or 4, as may be seen in Fig. 1. This was discussed at some length for WT (14). Once the heterogeneity is noted, it is sufficient for most purposes to consider an effective mean rate.



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 1.   Typical data for the rebinding of CO to C331A nNOS. In this case, CO (at 1 atm) is combining, after photolysis, with protein incubated overnight with 10 mM L-Arg and no BH4. The data illustrate the presence of two kinetic phases and show that the slow phase is not a perfect single exponential. In practice, the fast phase, shown as a steep drop in the main figure and expanded in the inset, would be recorded at a much higher time resolution to prove that it also is not a single exponential. In this figure, the fractional amplitudes of the two phases are nearly equal.

Mutant and WT proteins are also similar but not identical with respect to the mean value of the fast and slow rate constants for CO addition, as shown in Table I. The slow phase has a rate constant that is almost the same in all circumstances. The fast phase, however, has a rate constant in the mutant that is about twice as fast as in the WT holoenzyme and heme domain.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Rate constants for ligand binding to wild type nNOS and to C331A incubated 12 h
The CO reactions are with ferrous heme; the NO data are virtually identical for ferric and ferrous heme.

It is, however, the relative proportion of the two phases that is of the most interest. Whatever the interpretation of the two kinetic phases may be, the changes in their relative proportions as conditions are varied offer a critical test for comparing the behavior between WT and mutant preparations. Fig. 2 shows the fraction of the slow phase in two circumstances for C331A. It also includes, for comparison, data on the WT holoenzyme and data for a heme-binding domain (residues 1-714), both of which were reported previously (14). The fraction of the slow phase is at its maximum when both L-Arg and BH4 are bound. It is intermediate when just one or the other is present, and it is at its minimum when both are absent. In the WT holoenzyme (back row), the appearance of the slow phase requires much less than 1 mM L-Arg, and the association of L-Arg with protein occurs faster than we can carry out flash photolysis measurements, which require several minutes of signal averaging. In the C331A mutant, the effects associated with binding L-Arg and BH4 appeared only gradually after extended incubation. The mutant C331A could be forced to display 100% slow phase but only after more than 12 h of incubation with both BH4 and a large, 10 mM concentration of L-Arg (third row, left side). Lesser concentrations of L-Arg were not as effective. Either BH4 or L-Arg alone was not nearly as effective as is either alone in the WT protein. A 2-h incubation (second row) had little effect.



View larger version (129K):
[in this window]
[in a new window]
 
Fig. 2.   Percentage of amplitude in the slow phase for CO association with various nNOS preparations. Front row, results for the heme domain (HmDom) of the WT enzyme, incubated approximately 2 h. Second row, C331A incubated approximately 2 h. Third row, C331A incubated approximately 12 h. Back row, data for the WT holoenzyme, incubated approximately 2 h. Along each row, data labeled with B have 250 µM BH4; those labeled with A have 10, 1, or 0.1 mM L-Arg as indicated.

Fig. 2 (two front rows) shows that CO binding to C331A initially has some similarity to that in the heme domain of WT nNOS. Both BH4 and L-Arg must be present to achieve much slow phase. In both cases, the fraction of slow phase increases for the first few hours (data not shown). Incubation of the heme domain could not be extended to 12 h because of the excessive formation of the "P-420 analogue" (13, 18). Some formation of the P-420 feature also occurred in C331A, especially at low CO concentration and in the absence of BH4, consistent with previous reports of the factors involved in P-420 conversion (13, 18).

As with the WT holoenzyme and heme domain (14), flash photolysis of the CO-ligated C331A mutant displays, in addition to bimolecular association, nanosecond transient absorbance changes that are plausibly attributed to geminate recombination. In all cases, these nanosecond transients are larger whenever the fast phase is larger.

Ligand dissociation of CO was also characterized. Illustrative cases are shown in Table I. Dissociation in extensively incubated C331A is about a factor of 2 faster than in either the WT holoenzyme or heme domain. For both the WT holoenzyme and C331A with BH4 but without L-Arg, somewhat better fits were obtained by using two exponentials (for C331A + BH4, 33% at 0.92 s-1 plus 67% at 0.21 s-1, and for WT + BH4, 17% at 15 s-1 plus 83% at 0.16 s-1).

NO Ligation-- The association of nitric oxide with C331A was investigated briefly. Unlike CO, which binds only to ferrous iron, NO binds to both ferrous and ferric forms. Association of NO was virtually identical for ferric and ferrous C331A, as was true for WT protein (15). Fresh solutions of C331A displayed association rate constants of 1-2 × 107 M-1 s-1 with the faster rate in the absence of L-Arg and BH4 and the slower rate in the presence of both. This is identical to values reported previously for the WT heme domain (15). Table I shows the results for C331A samples incubated overnight with L-Arg. After incubation, the NO association constants match values measured previously for the WT holoenzyme (15), which are reduced by about a factor of 2 from the value for fresh C331A solutions and the heme domain. (These rate constants for NO are all mean rates; detailed fits showed heterogeneity, requiring comparable amplitudes of at least two exponentials differing by a small factor, around 5.) Photolysis of NO-ligated nNOS has only a small amplitude. Presumably much of the photolyzed NO undergoes geminate recombination before it can escape to the solvent. Because no geminate recombination was measured with the nanosecond spectrometer, it was determined that most geminate recombination must occur during time scales under a few nanoseconds.

Although it is unwise to overinterpret rate constants that vary by only a factor of 2, the essential finding for NO association parallels what was observed for CO ligation; incubation with L-Arg modifies behavior to make it more similar to WT holoenzyme and less like the heme domain fragment.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The principal changes in ligand binding kinetics brought about by the mutation C331A in nNOS were variations in the relative amount of fast and slow phases for CO binding. The rate of binding must reflect conditions in the distal "pocket" and/or tension exerted by the proximal ligand, which in nNOS happens to be a cysteine, but not Cys331. That the presence of bound L-Arg and/or BH4 increases the fraction of slow phase in the WT nNOS was well established by prior work. The first observation was reported by Matsuoka et al. (19) as a small part of a broad study. Our own more detailed study (14) confirmed the two phases (albeit with a larger 100-fold ratio in rate constants) and the effect of L-Arg on them but also added information about the effect of BH4, demonstrated that the two phases are each slightly heterogeneous, and showed that the oxygenase domain alone also displayed dual behavior but was biased much more toward the faster process. In addition, we used scavenging to measure dissociation rate constants near 0.3 s-1, and we detected substantial absorbance changes on nanosecond time scales, attributed to geminate recombination. Subsequently, Sato et al. (20) studied CO association with nNOS (rat). In the course of a study of a variety of substrates and inhibitors, they confirmed again that with both L-Arg and BH4 present, one observes essentially a single phase with the slow rate constant found earlier. They also reported careful measurements of equilibrium constants from which one may deduce a CO dissociation rate constant equal to 0.3 s-1, which is in agreement with our kinetic determination. Recently, Tetreau et al. (21) confirmed the 100-fold factor in rates between the two phases, the need for a distribution of rate constants within each phase, and the presence of nanosecond absorbance changes. They added information about CO association kinetics at cryogenic temperatures. In an effort to explain the differences between phases, they measured the hydrodynamic volume of the protein under different conditions. When the slow phase dominated, the volumes were reasonable for a globular protein of the mass of NOS. When the fast phase dominated, the hydrodynamic volume was 10-fold larger. They inferred that the fast-reacting form of nNOS involves either substantial unfolding of the protein or aggregation or both.

Native WT protein exists largely in the fast-reacting form in the absence of L-Arg and BH4, but it converts rapidly to the slow form even at low concentrations of those agents. Modifying the protein either by truncation to the oxygenase (heme) domain or by mutating C331A renders it more difficult to achieve the slow-reacting active form, but sufficiently large concentrations of L-Arg and extended incubation eventually accomplish much the same change that occurs more readily in the native holoenzyme. In the absence of BH4 and L-Arg, CO association with C331A behaves much like that in the WT heme domain fragment. Extended incubation restores almost normal behavior. The dissociation of CO, however, follows a slightly different pattern. The dissociation from the WT heme domain and WT holoenzyme is very similar, whereas CO dissociation from C331A is faster by a factor of 2 and remains so even after extended incubation with 10 mM L-Arg. This suggests that the restoration of the normal structure by incubation of C331A is not quite perfect.

Association with NO shows similar effects. There is only one phase for NO association under any condition, but there is a slight difference in the rate between the WT heme domain and WT holoenzyme. That difference is replicated in C331A before and after incubation.

Complementing the kinetic studies discussed here may be resonance Raman measurements of vibrational frequencies for ligands bound to heme. Recent publications (22, 23), building on earlier investigations cited therein, infer "open" and "closed" conformations for the immediate environment of the iron binding site with the open form correlating with the fast-reacting species observed in kinetic measurements and the closed form correlating with the slow-reacting form. A plausible inference is that both L-Arg and BH4 bind close to the iron, affecting both ligand access to and bonding with the iron. It is conceivable that their effect on ligation is attributable to simple steric blockage. However, it is more likely that the effects of L-Arg and BH4 are better described as inducing conformational change either in the distal pocket or at the proximal cysteine bond, or both. The Raman investigation of the immediate neighborhood of the iron explores a very different length scale than do the light-scattering studies that inferred different hydrodynamic volumes. Kinetic data involve both scales. There are presently too many uncertainties for us to propose a model that can explain the data from Raman spectroscopy, light-scattering measurements, and ligation kinetics. (For example, full understanding of kinetics requires data on geminate recombination in the picosecond regime.) However, some ideas may be inspired by crystal structures, which are starting to appear.

In rat brain nNOS, the C331A mutant involves substitution into the generally conserved motif (CXXXXC) of the two (identical) subunits as follows.

<SC><B><UP>Motif</UP></B></SC><B><UP> 1</UP></B>
A crystal structure of nNOS is not yet reported, but that of eNOS has been (24). In bovine eNOS the analogous position is Cys101, whereas in human eNOS it is Cys99. The four cysteines coordinate to a zinc in both eNOS (24) and nNOS.2 This ZnS4 center stabilizes the dimer interface and/or the flavoprotein-heme domain interface. (We have argued elsewhere (24) that iNOS also requires a similar, tetrahedrally coordinated zinc.) In the C331A mutant of nNOS, there are structural perturbations that make binding both BH4 and L-Arg more difficult, but sufficiently long incubation at large concentrations of L-Arg allows binding to occur. Once binding has occurred, a structure is stabilized that is similar to the native conformation and is kinetically active. Still, the incubated C331A is probably not quite identical to WT. The enzymatic activity of the incubated C331A is 84% of that in WT nNOS, and CO dissociation is twice as fast.

Cysteine 331 is not the heme-binding amino acid, nor is it involved directly in the binding of either BH4 or L-Arg. The question then is how the mutation C331A affects their binding. An explanation may be offered on the basis of the crystal structure data (24). Those data indicate that L-Arg is a structural mimic of BH4 and that L-Arg and BH cross-talk with each other through heme propionate. In eNOS, the BH4 hydrogen bonds to Ser104, which is a part of the chain that is connected to the zinc atom, which is tetrahedrally coordinated to the cysteine residues on the two chains of the dimer. Zinc is one of the few metals capable of readily forming tetrahedral (most often), octahedral, and square planar (occasionally) structures. Thus the structure around the zinc should be able to switch among multiple conformations. Any change in the stereochemistry around the zinc will be transmitted to the binding of BH4 (and in turn to the L-Arg through the heme-proprionate bridge) via Ser104 or its analog in nNOS. Thus the data from ligand binding kinetics and enzyme reactivity bring out rather dramatically the importance of the tetrahedrally coordinated zinc for functional integrity in the enzyme.


    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants HL30050 and GM52419 (to B. S. S. M. ) and Grant AQ-1192 from the Robert A. Welch Foundation (to B. S. S. M. ).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed. Tel.: 858-534-3199; Fax: 858-534-0130; E-mail: dmagde@ucsd.edu.

Published, JBC Papers in Press, November 6, 2000, DOI 10.1074/jbc.M007461200

2 C. S. Raman, H. Li, T. L. Poulos, P. Martásek, and B. S. S. Masters, unpublished observations.


    ABBREVIATIONS

The abbreviations used are: NOS, nitric-oxide synthase(s); NO, nitric oxide; CO, carbon monoxide; nNOS, neuronal nitric-oxide synthase; eNOS, endothelial nitric-oxide synthase; iNOS, inducible nitric-oxide synthase; BH4, tetrahydrobiopterin; WT, wild type.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES


1. Bredt, D. S., and Snyder, S. H. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 682-685[Abstract]
2. McMillan, K., Bredt, D. S., Hirsch, D. J., Snyder, S. H., Clark, J. E., and Masters, B. S. S. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11141-11145[Abstract]
3. White, K. A., and Marletta, M. A. (1992) Biochemistry 31, 6627-6631[Medline] [Order article via Infotrieve]
4. Stuehr, D. J., and Ikeda-Saito, M. (1992) J. Biol. Chem. 267, 20547-20550[Abstract/Free Full Text]
5. Klatt, P., Schmidt, K., and Mayer, B. (1992) Biochem. J. 288, 15-17[Medline] [Order article via Infotrieve]
6. Tayeh, M. A., and Marletta, M. A. (1989) J. Biol. Chem. 264, 19654-19658[Abstract/Free Full Text]
7. Kwon, N. S., Nathan, C. F., and Stuehr, D. J. (1989) J. Biol. Chem. 20496-20501
8. Mayer, B., John, M., and Böhme, E. (1990) FEBS Lett. 277, 215-219[CrossRef][Medline] [Order article via Infotrieve]
9. Martásek, P., Miller, R. T., Liu, Q., Roman, C. S., Salerno, J. C., Migita, C. T., Raman, C. S., Gross, S. S., Ikeda-Saito, M., and Masters, B. S. S. (1998) J. Biol. Chem. 273, 34799-34805[Abstract/Free Full Text]
10. Miller, R. T., Martásek, P., Raman, C. S., and Masters, B. S. S. (1999) J. Biol. Chem. 274, 14537-14540[Abstract/Free Full Text]
11. Wang, J., Rousseau, D. L., Abu-Soud, H. M., and Stuehr, D. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10512-10516[Abstract/Free Full Text]
12. Hurshman, A. R., and Marletta, M. A. (1995) Biochemistry 34, 5627-5634[Medline] [Order article via Infotrieve]
13. Wang, J., Stuehr, D. J., and Rousseau, D. L. (1995) Biochemistry 34, 7080-7087[Medline] [Order article via Infotrieve]
14. Scheele, J. S., Kharitonov, V. G., Martásek, P., Roman, L. J., Sharma, V. S., Masters, B. S. S., and Magde, D. (1997) J. Biol. Chem. 272, 12523-12528[Abstract/Free Full Text]
15. Scheele, J. S., Bruner, E., Kharitonov, V., Martásek, P., Roman, L. J., Masters, B. S. S., Sharma, V. S., and Magde, D. (1999) J. Biol. Chem. 274, 13105-13110[Abstract/Free Full Text]
16. Sharma, V. S., Isaacson, R. A., John, M. E., Waterman, M. R., and Chevion, M. (1983) Biochemistry 22, 3897-3902[Medline] [Order article via Infotrieve]
17. Olson, J. S. (1981) in Hemoglobins: Methods in Enzymology (Antonini, E. , Rossi-Bernardi, L. , and Chiancone, E., eds), Vol. 76 , pp. 631-651, Academic Press, NY
18. Huang, L., Abu-Soud, H. M., Hille, R., and Stuehr, D. J. (1999) Biochemistry 38, 1912-1920[CrossRef][Medline] [Order article via Infotrieve]
19. Matsuoka, A., Stuehr, D. J., Olson, J. S., Clark, P., and Ikeda-Saito, M. (1994) J. Biol. Chem. 269, 20335-20339[Abstract/Free Full Text]
20. Sato, H., Nomura, S., Sagami, I., Ito, O., Daff, O., and Shimuzu, T. (1998) FEBS Lett. 430, 377-380[CrossRef][Medline] [Order article via Infotrieve]
21. Tetreau, C., Tourbez, M., Gorren, A., Mayer, B., and Lavalette, D. (1999) Biochemistry 38, 7210-7218[CrossRef][Medline] [Order article via Infotrieve]
22. Wang, J., Stuehr, D. J., and Rousseau, D. L. (1997) Biochemistry 36, 4595-4606[CrossRef][Medline] [Order article via Infotrieve]
23. Renodon, A., Boucher, J.-L., Wu, C., Gachhui, R., Sari, M.-A., Mansuy, D., and Stuehr, D. (1998) Biochemistry 37, 6367-6374[CrossRef][Medline] [Order article via Infotrieve]
24. Raman, C. S., Li, H., Martásek, P., Kral, V., Masters, B. S. S., and Poulos, T. L. (1998) Cell 95, 939-950[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.